CompletedPhase 1

A Trial In Patients With Advanced Cancer And Leukemia

United States72 participantsStarted 2009-06-25

Plain-language summary

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available * Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available * Men and women \>16 years old Exclusion Criteria: * Prior treatment with a gamma secretase inhibitor for treatment of cancer * Patients taking Tamoxifen * Patients with active graft versus host disease * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness * Patients who are pregnant or breast feeding * Patients with clinical evidence of central nervous system disease

What they're measuring

Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)

Timeframe: Baseline to the end of Cycle 1 (Week 4)

Number of T-ALL/LBL Participants With First-Cycle DLT

Timeframe: Baseline to the end of Cycle 1 (Week 4)

Trial details

NCT IDNCT00878189

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-01-10

Results submitted2017-10-30

View on ClinicalTrials.gov More Neoplasms by Histologic Type trials